WASHINGTON — President Donald Trump unveiled a deal Thursday with drugmakers Eli Lilly and Novo Nordisk to expand coverage and reduce prices for the popular obesity treatments Zepbound and Wegovy.
Known as GLP-1 receptor agonists, the drugs have soared in popularity in recent years but patient access has been a problem because of their cost — around $500 a month for higher doses — and insurance coverage has been spotty. More than 100 million American adults have obesity, according to federal estimates.
Coverage of the drugs for obesity will expand to Medicare patients starting next year, according to the administration, which said some lower prices also will be phased in for patients without coverage. Starting doses of new, pill versions of the treatments also will cost $149 a month if they are approved.
“(It) will save lives, improve the health of millions and millions of Americans,” said Trump, in an Oval Office announcement in which he referred to GLP-1s as a “fat drug.”
Thursday’s announcement is the latest attempt by the Trump administration to rein in soaring drug prices in its efforts to address cost-of-living concerns among voters. Pfizer and AstraZeneca recently agreed to lower the cost of prescription drugs for Medicaid after an executive order in May set a deadline for drugmakers to lower prices on their own or face new limits on what the government will pay.
As with the other deals, it’s not clear how much the price drop will be felt by consumers. Drug prices can vary based on the competition for treatments and insurance coverage.
The obesity drugs work by targeting hormones in the gut and brain that affect appetite and feelings of fullness. In clinical trials, they helped people shed 15% to 22% of their body weight — up to 50 pounds or more in many cases.
Patients usually start on smaller doses and then work up to larger amounts, depending on their needs. They need to stay on the the treatments indefinitely or risk regaining weight, experts say.
The medications have proven especially lucrative for Lilly and Novo. Lilly said recently that sales of Zepbound have tripled so far this year to more than $9 billion.
But for many Americans, their cost has made them out of reach.
Medicare, the federally funded coverage program mainly for people ages 65 and over, now covers the cost of the drugs for conditions such as type 2 diabetes and cardiovascular disease, but not for weight loss alone. Trump’s predecessor, Joe Biden, proposed a rule last November that would have changed that, but the Trump administration nixed it.
Few state and federally funded Medicaid programs, for people with low incomes, offer coverage. And employers and insurers that provide commercial coverage are wary of paying for these drugs in part because so many people might use them.
The $500 monthly price for higher doses of the treatments also makes them unaffordable for those without insurance, doctors say.
“Trump is the friend of the forgotten American,” said Health and Human Services Secretary Robert F. Kennedy, Jr. at Thursday’s announcement. “Obesity is a disease of poverty. And overwhelmingly these drugs have only been available for people who have wealth.”
(Obesity rates actually are slightly higher for middle-income Americans than they are for those with the lowest and highest incomes, according to 2017-2020 data collected by the U.S. Centers for Disease Control and Prevention.)
Kennedy had previously expressed skepticism about GLP-1s, but he was full of praise for Trump for pushing to help a broader segment of Americans have access to the drug.
Lower prices also will be phased in for people without coverage through the administration’s TrumpRx program, which will allow people to buy drugs directly from manufacturers, starting in January.
Administration officials said the average price of the drugs sold on TrumpRx will start at around $350 and then drop to $245 over the next two years.
A Novo Nordisk spokesperson declined to provide details on their pricing changes.
Lilly said it will sell starter doses of Zepbound for $299 a month and additional doses at up to $449. Both represent $50 reductions from current prices for doses it sells directly to patients.
Administration officials said lower prices also will be provided for state and federally funded Medicaid programs. And starting doses of new, pill versions of the obesity treatments will cost $149 a month if they are approved.
U.S. health regulators said separately that they will dramatically expedite their review of the pill versions.
Want more insights? Join Working Title - our career elevating newsletter and get the future of work delivered weekly.
